Top 10 Oncology Capital Raises and Investors in the U.S. – January 1st – 31st, 2026
Several interesting transactions closed in the Oncology sector last month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Altimmune, clinical-stage biopharmaceutical company that develops treatments for obesity, metabolic diseases, and liver diseases, received $75 million of development capital through a private placement.
- Estrella Immunopharma, clinical-stage biopharmaceutical company that develops CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors, received $8 million of development capital through a private placement.
Merger/Acquisition
-
- Hera BioLabs, pre-clinical drug development services, that develops cell-line modification and animal model creation, was acquired by Demeetra.
- Mersana Therapeutics, clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs, was acquired by Day One Biopharmaceuticals for $127.251 million.
Later Stage VC
-
- Recludix Pharma, drug discovery company that treats cancer and autoimmune diseases, raised an estimated $21.5 million of Series B venture funding from Access Biotechnology, Eli Lilly and Westlake Village BioPartners.
- Reglagene, therapeutics company that transforms tubulin targeting therapy for central nervous system diseases, raised venture funding from CANCER FUND, Viva BioInnovator and Angel Star Ventures.
Early Stage VC
-
- Monimoi Therapeutics, transformative therapies that harnesses the potential of covalent medicines and chemical proteomics, raised venture funding from Regeneron Ventures, Mass General Brigham Ventures and Catalio Capital Management.
- TwoStep Therapeutics, biotechnology company that develops novel tumor-targeting therapeutics for solid tumors, raised $21.11 million of Series A venture funding from 2048 Ventures, NFX and other investors.
Seed
-
- Fortitude Biomedicines, biologic therapies for therapeutic discovery and advancement, raised $13 million of seed funding in a deal led by Shanghai Healthcare Capital, K2VC, and Elikon Venture.
- Vivere Oncotherapies, gene therapy delivery technologies that improves immunotherapy for immunologically cold solid tumors, raised $8.89 million of seed funding in a deal led by YK Bioventures.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
Gary Levy
Managing Director
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
